Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc.（THRX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · THRX · 截至 2026年6月9日
活动摘要
买入笔数
6
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Theseus Pharmaceuticals, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
THRX 季度内部人买卖趋势
THRX 内幕交易卖出 · THRX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
THRX 高管卖出股份 · THRX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Feb 14, 2024 | ORBIMED ADVISORS LLC Director | Other | 650,600 | $2.63M⚡ | Form 4 |
| Feb 14, 2024 | HAYDEN DONALD J JR Director | Other | 10,000 | $41K | Form 4 |
| Feb 14, 2024 | GORDON CARL L Director | Other | 650,600 | $2.63M⚡ | Form 4 |
| Feb 14, 2024 | Dukes Iain D. Director | Other | 388,324 | $1.57M⚡ | Form 4 |
| Feb 14, 2024 | Dahms Bradford D. President and CFO | Other | 8,150.225 | $33K | Form 4 |
| Nov 6, 2023 | Shakespeare William See Remarks | Option | 251,084 | $80K | Form 4 |
| Jul 17, 2023 | GORDON CARL L Director | Purchase | 328,482 | $1.00M⚡ | Form 4 |
| Jul 17, 2023 | GORDON CARL L Director | Purchase | 151,450 | $462K | Form 4 |
| Jul 17, 2023 | ORBIMED ADVISORS LLC Director | Purchase | 328,482 | $1.00M⚡ | Form 4 |
| Jul 17, 2023 | ORBIMED ADVISORS LLC Director | Purchase | 151,450 | $462K | Form 4 |
| Jul 17, 2023 | Foresite Capital Management V, LLC 10 percent owner | Purchase | 523,450 | $1.55M⚡ | Form 4 |
| Jul 17, 2023 | Foresite Capital Management V, LLC 10 percent owner | Purchase | 176,550 | $524K | Form 4 |
| Dec 29, 2022 | Foresite Capital Management V, LLC Director | Purchase | 250,000 | $1.25M⚡ | Form 4 |
| Dec 29, 2022 | Foresite Capital Management V, LLC Director | Purchase | 250,000 | $1.25M⚡ | Form 4 |
| Dec 30, 2022 | HAYDEN DONALD J JR Director | Purchase | 9,900 | $49K | Form 4 |
| Dec 29, 2022 | HAYDEN DONALD J JR Director | Purchase | 100 | $500 | Form 4 |
| Nov 30, 2022 | Dahms Bradford D. CFO | Purchase | 1,502.189 | $10K | Form 4 |
| Nov 11, 2022 | CLACKSON TIMOTHY P President and CEO | Purchase | 2,500 | $17K | Form 4 |
| Nov 7, 2022 | GORDON CARL L Director | Purchase | 192,000 | $1.00M⚡ | Form 4 |
| Nov 7, 2022 | ORBIMED ADVISORS LLC Director | Purchase | 192,000 | $1.00M⚡ | Form 4 |
| Jan 21, 2022 | GORDON CARL L Director | Purchase | 111,896 | $1.12M⚡ | Form 4 |
| Jan 20, 2022 | GORDON CARL L Director | Purchase | 35,000 | $348K | Form 4 |
| Jan 19, 2022 | GORDON CARL L Director | Purchase | 11,521 | $115K | Form 4 |
| Jan 21, 2022 | ORBIMED ADVISORS LLC Director | Purchase | 111,896 | $1.12M⚡ | Form 4 |
| Jan 20, 2022 | ORBIMED ADVISORS LLC Director | Purchase | 35,000 | $348K | Form 4 |
Foresite Capital Management V, LLC
10 percent owner
日期
Jul 17
股数
523,450
均价
$2.97
总金额
$1.55M ⚡
Foresite Capital Management V, LLC
10 percent owner
日期
Jul 17
股数
176,550
均价
$2.97
总金额
$524K
Foresite Capital Management V, LLC
Director
日期
Dec 29
股数
250,000
均价
$5.00
总金额
$1.25M ⚡
Foresite Capital Management V, LLC
Director
日期
Dec 29
股数
250,000
均价
$5.00
总金额
$1.25M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 THRX 内幕交易
THRX 内幕交易
Theseus Pharmaceuticals, Inc.（THRX）内幕交易数据来源于公司内部人（包括THRX）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。THRX内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Theseus Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
THRX 内幕交易 · 5个问题Theseus Pharmaceuticals, Inc.（THRX）的内部人包括高管和董事，如THRX等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026